Impact of Premedication De-Escalation on Incidence of Infusion-Related Reactions With Daratumumab.

Donna Vazirnia Alejandro Del Rio Verduzco Scott A SoefjeKristyn A SandersTyler B Sandahl

Published in: JCO oncology practice (2024)

Omission of premedications after cycle 1 of daratumumab did not increase the incidence of infusion. Premedications may safely be omitted after cycle 1 of daratumumab when administered by the SC route.

Keyphrases

multiple myeloma
risk factors
low dose
open label
clinical trial
study protocol